GlassScriptPhysician profile
Ali C Shapiro
NPI 1790268795
$3,901.12
in general payments reported to CMS, 2019-2025
28 companies · $754 in 2025
The $754 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.92 · 2022: $216 · 2023: $1,416 · 2024: $1,468 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,638.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $589.10 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $534.54 | 2023-2025 | |
| Pfizer INC. | $474.68 | 2023-2025 | |
| Novo Nordisk INC | $473.31 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $420.14 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $191.87 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Glaxosmithkline, LLC. | $186.32 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $163.41 | 2022-2024 | |
| Exact Sciences Corporation | $136.64 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $116.85 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.04 | 2022-2025 | Jardiance, Ofev |
| Dexcom, INC. | $79.88 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $75.09 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.60 | 2022-2023 | Trulance, Xifaxan |
| Actelion Pharmaceuticals US, INC. | $41.77 | 2024 | Opsumit, Uptravi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $38.39 | 2022-2023 | |
| Axsome Therapeutics, INC. | $32.97 | 2024 | Auvelity |
| Qol Medical, LLC | $31.45 | 2023 | Sucraid |
| Edwards Lifesciences Corporation | $28.98 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Phathom Pharmaceuticals, INC. | $21.20 | 2024 | Voquezna |
| Becton, Dickinson and Company | $18.14 | 2024 | Bd Onclarity |
| Biohaven Pharmaceutical Holding Company LTD. | $16.98 | 2022 | |
| Lucid Diagnostics INC. | $16.17 | 2023 | |
| Abbott Laboratories | $15.77 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $15.65 | 2023 | Nexletol |
| Sanofi Pasteur INC. | $14.95 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.85 | 2021 | |
| Merck Sharp & Dohme LLC | $13.38 | 2024 | Gardasil, Vaqta, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.